Dr. Venkata K. Parsa, MD | Fort Myers ...

Dr. Venkata K. Parsa

Claim this profile

Regional Cancer Center-Lee Memorial Health System

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
29 drugs studied

Area of expertise

1Lung Cancer
Venkata K. Parsa has run 3 trials for Lung Cancer. Some of their research focus areas include:
Stage II
Stage III
Stage I
2Non-Small Cell Lung Cancer
Venkata K. Parsa has run 2 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage II
Stage III
Stage I

Affiliated Hospitals

Image of trial facility.
Regional Cancer Center-Lee Memorial Health System

Clinical Trials Venkata K. Parsa is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Bupropion

for Fatigue in Breast Cancer Survivors

This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.
Recruiting1 award Phase 38 criteria

More about Venkata K. Parsa

Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Venkata K. Parsa has experience with
  • Gemcitabine Hydrochloride
  • Carboplatin
  • Paclitaxel
  • Pembrolizumab
  • Pemetrexed Disodium
  • Biospecimen Collection

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Venkata K. Parsa specialize in?
Is Venkata K. Parsa currently recruiting for clinical trials?
Are there any treatments that Venkata K. Parsa has studied deeply?
What is the best way to schedule an appointment with Venkata K. Parsa?
What is the office address of Venkata K. Parsa?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security